Acquired Factor X Deficiency in Light Chain Amyloidosis: A Report of 2 Korean Cases by Ma, Youngeun et al.
154     www.kjlm.org
Acquired Factor X Deficiency in Light Chain Amyloidosis: 
A Report of 2 Korean Cases
Youngeun Ma, M.D.
1, Eui-Hoon Kwon, M.T.
1, Jung-Eun Lee, M.D.
2, Kihyun Kim, M.D.
2, Hee-Jin Kim, M.D.
1, 
and Sun-Hee Kim, M.D.
1
Departments of Laboratory Medicine & Genetics
1 and Medicine
2, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Amyloidosis is a heterogeneous group of diseases in which misfolding of extracellular proteins is the pathogenic factor. Light chain 
amyloidosis (AL) is the most common form of amyloidosis, and the causative proteins in AL are the immunoglobulin light chains 
produced by clonal plasma cells. Hemorrhagic events, ranging from mild subcutaneous hemorrhage to life-threatening bleeding, 
account for a significant proportion of morbidities and mortality in AL patients. Deficiency of factor X from deposition into amyloid 
fibrils has been reported to be the most common acquired factor deficiency in AL. We herein report 2 patients with acquired factor 
X deficiency in AL. A 55-yr-old woman with AL had a prolonged prothrombin time (PT) and an activated partial thromboplastin 
time (aPTT) of 2.51 International Normalized Ratio (INR) and 75.1 sec, respectively, which were corrected on mixing with normal 
plasma. Factor X activity was markedly decreased at 5%. The other patient was a 67-yr-old man with AL with a PT of 1.63 INR and 
an aPTT of 50.3 sec, which were corrected on mixing with normal plasma. Factor X activity was decreased at 17%. Neither of the 
patients had apparent hemorrhagic manifestations. Identification of acquired factor deficiency and timely coagulation tests are 
needed in the diagnostic workup and management in AL.
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Amyloidosis is a heterogeneous group of diseases in which 
misfolding of extracellular protein is the pathogenic factor. 
This process produces insoluble, toxic protein aggregates 
that are deposited in tissues in bundles of β-sheet fibrillar 
protein [1]. The most common cause of amyloidosis is 
clonal plasma cells in the bone marrow producing immu-
noglobulins that are amyloidogenic (light chain amyloidosis 
or AL) [2]. Hemorrhagic events, ranging from mild subcu-
taneous hemorrhage to life-threatening bleeding, account 
for a significant proportion of morbidities and mortality in 
AL. Bleeding tendency is frequently encountered in AL, and 
while mild subcutaneous hemorrhage is the most common 
manifestation, life-threatening bleeding has also been re-
ported [3-6]. Acquired hemostatic abnormalities, including 
coagulation factor deficiencies, hyperfibrinolysis, and plate-
let dysfunction are the background of bleeding tendency [5, 
6]. In particular, acquired deficiency of factor X is the most 
common coagulation factor deficiency in patients with AL, 
and it is postulated to occur via the adsorption of factor X to 
amyloid fibrils [3, 5-8]. We herein report 2 Korean patients 
with acquired factor X deficiency in association with AL.
CASE REPORTS
1. Patient 1
A 55-yr-old woman with generalized edema was diag-
nosed with AL on the basis of a renal biopsy. Serum and 
urine electrophoresis combined with immunofixation re-
vealed M-protein of IgG/lambda type, and bone marrow 
analysis showed monoclonal proliferation of plasma cells. 
Coagulation tests revealed a prolonged prothrombin time 
(PT) of 2.51 International Normalized Ratio (INR) and an 
activated partial thromboplastin time (aPTT) of 75.1 sec Ma Y, et al.  •  Acquired FX Deficiency in Amyloidosis
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(29.1-41.9 sec). Thrombin time was within the normal range 
(18.6 sec; reference interval, 15.6-20.0 sec). Complete cor-
rection of the prolonged PT and aPTT on mixing with nor-
mal plasma prompted us to proceed with factor assays, 
which revealed markedly decreased factor X activity at 5% 
(69-126%) and mildly decreased factor V activity 63% (81-
160%). The patient had no apparent bleeding symptoms. 
The patient underwent autologous peripheral blood stem 
cell transplantation and achieved complete hematological 
remission. Follow-up coagulation tests revealed improve-
ment of prolonged PT/aPTT (PT, 1.77 INR and aPTT, 52.5 
sec) and normalization of factor V activity (136%). How-
ever, factor X activity was still decreased at 12%. Despite the 
improvement of coagulopathy, the patient experienced 
bleeding diathesis during the follow up for chronic kidney 
disease.
2. Patient 2
A 67-yr-old man with dyspnea was diagnosed with car-
diac amyloidosis. Monoclonal immunoglobulins of IgG/
kappa type were detected in the serum and urine, and bone 
marrow analysis showed an increase of monoclonal plasma 
cells. Coagulation tests showed prolongation of both PT 
(1.63 INR) and aPTT (50.3 sec), which were corrected on 
mixing with normal plasma. Thrombin time test was not 
performed. Factor assays revealed a significant decrease of 
factor X activity at 17%. Other coagulation factor activities 
were not decreased. He had no apparent bleeding manifesta-
tions. He received chemotherapy, and follow-up coagulation 
tests showed a normalized aPTT, but the PT was still pro-
longed (1.64 INR). Follow up for factor X activity was not 
performed.
DISCUSSION
Acquired factor deficiency with or without bleeding sy-
mptoms is not infrequent in AL, whereas it is rare in other 
types of amyloidosis. Specific coagulation factor deficiencies 
in AL have long been recognized and have been explained 
by the adsorption of coagulation factors to amyloid fibrils. 
Evidence showing the interaction of amyloidogenic light 
chains with coagulation factors and anecdotal reports of 
improved hemostasis after removal of amyloidotic spleen 
support the fact that coagulation factors bind to the amyloid 
fibrils [5]. Both isolated coagulation factor deficiency and 
combined deficiencies have been reported. Factor X defi-
ciency has been described as the most common acquired 
coagulation factor deficiency, affecting up to one-third of 
patients with AL. Deficiencies of other coagulation factors 
such as II, V, VII, and IX have also been reported [5-7]. Ac-
cording to a previous study that evaluated a total of 368 pa-
tients with AL, 32 patients had a factor X activity below 50% 
of normal. Eighteen of these patients (56%) had bleeding 
complications, which were more severe in the 12 patients 
with factor X activity below 25% of normal [7]. The 2 pa-
tients with acquired factor X deficiency from AL described 
in the present report had no bleeding symptoms, even with 
the very low level of factor X activity (5%) in Patient 1. A re-
view of the literature revealed a single case report on ac-
quired factor X deficiency in AL patients in Korea [9]. Kim 
et al. [9] reported factor X deficiency in a patient with AL 
and nephrotic syndrome. The patient had mildly decreased 
factor X activity of 49% (70-120%), prolonged PT of 1.32 
INR and upper normal aPTT of 39.4 sec (32-41.2 sec). De-
spite normal aPTT, mildly prolonged PT, and slightly de-
creased factor X activity, he had bleeding tendency and 
symptoms such as petechiae.
Previous studies reported that high-dose chemotherapy 
followed by autologous stem cell transplantation led to 
complete remission and normalization of the factor X level 
[7, 10, 11]. Patient 1 achieved complete remission after che-
motherapy and autologous peripheral blood stem cell trans-
plantation. The patient showed improvement of prolonged 
PT and aPTT (2.51 to 1.77 INR and 75.1 to 52.5 sec, respec-
tively). However, factor X activity was still significantly de-
creased (12%), and the patient developed bleeding diathesis 
during the course of treatment. Indeed, it was reported that 
the baseline factor X level was not predictive of bleeding 
risk, and optimal management of factor X deficiency in AL 
is still elusive [12]. The findings in the previously reported 
patient [9] and the 2 patients described in the present re-
port demonstrate the heterogeneous clinical and laboratory 
manifestations of factor X deficiency in Korean patients 
with AL.
To the best of our knowledge, this is only the second re-
port of factor X deficiency in association with AL in Korea. 
Further prospective studies involving multiple institutions 
are needed to investigate the epidemiology and clinical im-
plications of acquired factor X deficiency in Korean patients 
with AL. Appropriate coagulation workup should be condu-
cted in patients with AL with prolonged coagulation times, 
and further studies are needed to obtain laboratory and 
clinical data to delineate the frequency and clinical implica-
tions of acquired coagulopathy in Korean patients with AL.
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